<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00790699</url>
  </required_header>
  <id_info>
    <org_study_id>TDE 001</org_study_id>
    <nct_id>NCT00790699</nct_id>
  </id_info>
  <brief_title>Safety Study of Using Symlin Alongside Insulin in a Multiple Injection Port</brief_title>
  <official_title>A Randomized, Parallel, Single Center, Comparison, Pilot Study Evaluating the Safety and Efficacy of Using Symlin Alongside Insulin in a Multiple Injection Port (I-PORT)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Texas Diabetes &amp; Endocrinology, P.A.</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Amylin Pharmaceuticals, LLC.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Texas Diabetes &amp; Endocrinology, P.A.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine whether injecting Symlin and insulin through a&#xD;
      multiple injection port is safe and effective. This will be measured by HbA1c values taken at&#xD;
      the beginning of the study and at the final visit.&#xD;
&#xD;
      The secondary objective of the study is to measure patient satisfaction toward using the&#xD;
      multiple injection port.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The primary objective of this clinical study is to demonstrate the safety and efficacy of&#xD;
      giving pramlintide and insulin in the same multi-port injection device (I-PORT™). Efficacy&#xD;
      was measured by HbA1c values taken at baseline and the final visit&#xD;
&#xD;
      The secondary objective of this study is to measure patient satisfaction, opinions and&#xD;
      attitudes toward using the I-PORT™ for insulin and pramlintide administration compared to&#xD;
      standard insulin and pramlintide injections. The secondary safety and efficacy evaluations&#xD;
      included weight, Glycomark, 7-point SMBG evaluations, CGMS evaluations, incidence of glucose&#xD;
      values &gt; 300 mg/dl, incidence of glucose values &lt; 70 mg/dl, and insulin dose before the study&#xD;
      period, at month 1, 2 and 3.&#xD;
&#xD;
      The primary patient satisfaction evaluations included Quality of Life Questionnaire and&#xD;
      treatment satisfaction questionnaires.&#xD;
&#xD;
      The I-PORT™ is a disposable, low profile injection port through which insulin is injected&#xD;
      subcutaneously from a standard syringe or insulin pen.(Figure 1) The I-PORT™ allows multiple&#xD;
      insulin injections for up to 72 hours. Once the device is applied, the insertion needle is&#xD;
      removed and the cannula remains underneath the skin, serving as a delivery channel into the&#xD;
      SQ tissue- one skin puncture every three days. To use the device, the subject places the&#xD;
      needle on an injection device, such as a syringe or insulin pen, through the re-sealable&#xD;
      septum at the top of the I-PORT™ and injects medication directly into the delivery channel.&#xD;
&#xD;
      Study participants included male and females ages 18 and older who were utilizing a regimen&#xD;
      of at least two injections daily of rapid acting insulin and at least two injections daily of&#xD;
      pramlintide (Symlin®) with an HbA1c between &gt;6.5 and &lt; 9.0%.&#xD;
&#xD;
      There were 39 patients screened for the study and 8 screen failures leaving 31 subjects ages&#xD;
      18 and older, diagnosed with type 1 or type 2 diabetes mellitus for a minimum of six months.&#xD;
      1 patient dropped out of the study due to an AE and 30 completed the study.&#xD;
&#xD;
      A Randomized, Open-Label, Parallel, Single Center, Comparison Study. Approximately 13&#xD;
      patients with type 1 diabetes and 18 patients with type 2 diabetes were randomized into one&#xD;
      of two treatment groups. The randomization was stratified within diabetes type (1 vs. 2) and&#xD;
      low (6.5-7.5) vs. high (7.6-9.0) HbA1c level. The randomization process was executed using a&#xD;
      computer generated randomization table.&#xD;
&#xD;
      Subject Groups:&#xD;
&#xD;
        -  Group 1- Study subjects administered insulin and pramlintide using standard injection&#xD;
           therapy during the entire duration of the trial&#xD;
&#xD;
        -  Group 2- Study subjects administered insulin and pramlintide via a single I-PORT™ for&#xD;
           the entire duration of the trial&#xD;
&#xD;
      This study consisted of 8 visits: Screening/Visit 1, Visit 1a (Day -3), Visit 2 (Baseline/Day&#xD;
      0), Visit 3(Day 14), Visit 4(Month 1), Visit 5(Month 2), Visit 5a (Day 81) Visit 6(Month 3).&#xD;
&#xD;
      Subjects participating in this protocol were asked to take their rapid acting insulin&#xD;
      preparations and Pramlintide (Symlin®) at the same time using the dose called for by their&#xD;
      prescribed regimen established prior to study entry. Subjects used their usual type of&#xD;
      insulin preparations obtained by prescription from the commercial pharmacy system. Subjects&#xD;
      randomized into Group 2 were given guided instruction on the proper technique of insertion,&#xD;
      use and removal of the I-PORT™.&#xD;
&#xD;
      I-PORT™ devices were provided to the subjects and dispensed throughout the trial. Pramlintide&#xD;
      (Symlin) was supplied by Amylin Pharmaceuticals.&#xD;
&#xD;
      Patients performed a 7 point SMBG test 3-5 days at baseline and all subjects were instructed&#xD;
      on use of a Continuous Glucose Monitoring System (Medtronic iPro). The sensor was inserted&#xD;
      for 3-day wear at baseline and blood samples for HbA1c and Glycomark testing were obtained.&#xD;
      All subjects completed treatment satisfaction and QoL questionnaires. Each subject was&#xD;
      randomized to one of two possible treatment groups.&#xD;
&#xD;
      At each visit, subject diaries were reviewed, weight measurement and a site insertion exam&#xD;
      were performed. AEs and concomitant medications were reviewed at each visit.&#xD;
&#xD;
      Patients were asked to do a 7 point SMBG test 3-5 days prior to visit 3,4,5, and 5a. At visit&#xD;
      5a subjects were again instructed on use of a CGMS and a sensor was inserted for 3-day wear.&#xD;
&#xD;
      At the final visit (visit 6), the CGMS was removed and treatment satisfaction and QoL&#xD;
      questionnaires were completed by all subjects, and blood samples were taken for HbA1c and&#xD;
      Glycomark testing.&#xD;
&#xD;
      Patients were instructed to contact the site if they had 2 glucoses in a row &gt; 300 mg/dl or 2&#xD;
      glucoses in a row of &lt;70 mg/dl. Insulin and/or Pramlintide (Symlin®) were adjusted by PI as&#xD;
      needed throughout the trial. Discontinuation of I-PORT™ use was at the discretion of the PI&#xD;
      as a rescue measure.&#xD;
&#xD;
      The following QoL questionnaires/ Treatment satisfaction questionnaires were obtained from&#xD;
      patients at screening and at the final visit: DSTQ, DSTQ-c, DDS, TSQ,I-PORT™ Device Benefits,&#xD;
      Insulin/Symlin Satisfaction Questionnaire, I-PORT™ Device Management, General Diabetes&#xD;
      Management, I-PORT™ Device Satisfaction&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Lack of patient population&#xD;
  </why_stopped>
  <start_date>August 2009</start_date>
  <completion_date type="Actual">November 2011</completion_date>
  <primary_completion_date type="Actual">November 2011</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The Primary Outcome Will be Measured by HbA1c Values Taken at Screening, Baseline and After Three Months.</measure>
    <time_frame>3 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>The Secondary Outcome Will Measure Patient Satisfaction, Opinions and Attitudes Toward Using the Multiple Injection Port for Insulin and Symlin Administration Compared to Standard Symlin Injections (Measured Through Using Questionnaires).</measure>
    <time_frame>3 months</time_frame>
    <description>Scores from the QOL and treatment satisfaction measures collected at Visit 1 and Visit 6.&#xD;
To determine if patient satisfaction and patient opinions and attitudes toward using the I-PORT™ for insulin and Symlin® administration compared to standard insulin and Symlin® injections was significantly different for patients in the treatment and control groups, repeated-measures analysis of variance (RM-ANOVA) was conducted on scores from the quality of life and treatment satisfaction measures collected at Visit 1 and Visit 6. The RM-ANOVA results were evaluated to determine if any statistically significant changes occurred. TSQ- lower numbers show less satisfied. DDS- Lower numbers show decrease in distress. DTSQ- Lower numbers show less satisfied. One patient did not complete Visit 6 questionnaires.&#xD;
Scale ranges:&#xD;
DDS scale range: 17- 102 DTSQc scale range: 16- 96 Insulin /Symlin Treatment Satisfaction Questionnaire scale range: 15-90</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">31</enrollment>
  <condition>Type 1 Diabetes</condition>
  <condition>Type 2 Diabetes</condition>
  <arm_group>
    <arm_group_label>I-PORT</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Treatment group</description>
  </arm_group>
  <arm_group>
    <arm_group_label>standard injections</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>control group</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>I-PORT</intervention_name>
    <description>The study will compare injecting Symlin and insulin into a multiple injection port (I-PORT) vs. standard injections.</description>
    <arm_group_label>I-PORT</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>standard injections</intervention_name>
    <description>The study will compare injecting Symlin and insulin into a multiple injection port (I-PORT) vs. standard injections.</description>
    <arm_group_label>standard injections</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  male or female ages 18 and up&#xD;
&#xD;
          -  utilizing a regimen of at least two injections daily of insulin and at least two&#xD;
             injections daily of Symlin&#xD;
&#xD;
          -  able to understand and sign an informed consent form and HIPPA form&#xD;
&#xD;
          -  agrees to all study visits and procedures&#xD;
&#xD;
          -  HbA1c between &gt;6.5 and &lt;9.0 (inclusive)&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  history or current diagnosis of chronic disease which in the view of the PI would&#xD;
             interfere with adequate involvement in and completion of the requirements of the study&#xD;
&#xD;
          -  history of malignancy with in the last five years of study entry (other than basal&#xD;
             cell carcinoma)&#xD;
&#xD;
          -  current use of any drugs that alter gastrointestinal motility (e.g., anticholinergic&#xD;
             agents such as atropine), agents that slow intestinal absorption of nutrients (e.g.&#xD;
             a-glucosidase inhibitors) or promotility agents (e.g. metaclopromide)&#xD;
&#xD;
          -  any contraindication of Symlin or I-PORT according to the package labeling&#xD;
&#xD;
          -  are female and pregnant, lactating or planning to become pregnant during the duration&#xD;
             of the trial&#xD;
&#xD;
          -  are poorly compliant with their current insulin and/or Symlin regimen, as defined by&#xD;
             their HCP&#xD;
&#xD;
          -  has history of known hypersensitivity to plastics or polymers&#xD;
&#xD;
          -  treatment with any investigational drug within one month prior to enrollment&#xD;
&#xD;
          -  myocardial infarction or stroke within six months prior to screening&#xD;
&#xD;
          -  initiated use of Symlin pen or any Insulin pen in lieu of a vial in last 4 weeks (pen&#xD;
             use is okay as long as they have been using it for at least 4 weeks prior to screening&#xD;
             visit)&#xD;
&#xD;
          -  female subjects of childbearing potential practicing inadequate birth control&#xD;
             (adequate birth control is defined as using oral contraceptives, double barrier&#xD;
             methods, Intrauterine devices, surgical sterilization or vasectomized partner)&#xD;
&#xD;
          -  have confirmed diagnosis of gastroparesis&#xD;
&#xD;
          -  have hypoglycemia unawareness&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Thomas C. Blevins, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Texas Diabetes &amp; Endocrinology</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Texas Diabetes &amp; Endocrinology, PA</name>
      <address>
        <city>Austin</city>
        <state>Texas</state>
        <zip>78731</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>September 2020</verification_date>
  <study_first_submitted>November 10, 2008</study_first_submitted>
  <study_first_submitted_qc>November 12, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 13, 2008</study_first_posted>
  <results_first_submitted>May 6, 2014</results_first_submitted>
  <results_first_submitted_qc>September 28, 2020</results_first_submitted_qc>
  <results_first_posted type="Actual">October 20, 2020</results_first_posted>
  <last_update_submitted>September 28, 2020</last_update_submitted>
  <last_update_submitted_qc>September 28, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">October 20, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Texas Diabetes &amp; Endocrinology, P.A.</investigator_affiliation>
    <investigator_full_name>Thomas C. Blevins, M.D.</investigator_full_name>
    <investigator_title>Thomas Blevins, MD</investigator_title>
  </responsible_party>
  <keyword>diabetes</keyword>
  <keyword>Symlin</keyword>
  <keyword>pramlintide acetate</keyword>
  <keyword>insulin</keyword>
  <keyword>multiple injection port</keyword>
  <keyword>I-PORT</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus</mesh_term>
  </condition_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>I-PORT</title>
          <description>I-PORT: The study will compare injecting Symlin and insulin into a multiple injection port (I-PORT) vs. standard injections.</description>
        </group>
        <group group_id="P2">
          <title>Standard Injections</title>
          <description>standard injections: The study will compare injecting Symlin and insulin into a multiple injection port (I-PORT) vs. standard injections. The standard injections are usually 3-4 times daily.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="17"/>
                <participants group_id="P2" count="14"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="16"/>
                <participants group_id="P2" count="14"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>I-PORT</title>
          <description>I-PORT: The study will compare injecting Symlin and insulin into a multiple injection port (I-PORT) vs. standard injections.</description>
        </group>
        <group group_id="B2">
          <title>Standard Injections</title>
          <description>standard injections: The study will compare injecting Symlin and insulin into a multiple injection port (I-PORT) vs. standard injections.</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="17"/>
            <count group_id="B2" value="14"/>
            <count group_id="B3" value="31"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="14"/>
                    <measurement group_id="B2" value="13"/>
                    <measurement group_id="B3" value="27"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="45" spread="16.38"/>
                    <measurement group_id="B2" value="54" spread="10.60"/>
                    <measurement group_id="B3" value="49.5" spread="13.49"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="12"/>
                    <measurement group_id="B2" value="13"/>
                    <measurement group_id="B3" value="25"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ethnicity (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="4"/>
                    <measurement group_id="B3" value="6"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Not Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="15"/>
                    <measurement group_id="B2" value="10"/>
                    <measurement group_id="B3" value="25"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="2"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="16"/>
                    <measurement group_id="B2" value="13"/>
                    <measurement group_id="B3" value="29"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="17"/>
                    <measurement group_id="B2" value="14"/>
                    <measurement group_id="B3" value="31"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Glycomark</title>
          <units>ug/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="6.49" spread="3.69"/>
                    <measurement group_id="B2" value="5.05" spread="3.71"/>
                    <measurement group_id="B3" value="5.84" spread="3.71"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Type of Diabetes Breakdown</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>Type 1 Diabetics</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="7"/>
                    <measurement group_id="B2" value="6"/>
                    <measurement group_id="B3" value="13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Type 2 Diabetes</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="10"/>
                    <measurement group_id="B2" value="8"/>
                    <measurement group_id="B3" value="18"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Type 1 diabetes</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="7"/>
                    <measurement group_id="B2" value="6"/>
                    <measurement group_id="B3" value="13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>The Primary Outcome Will be Measured by HbA1c Values Taken at Screening, Baseline and After Three Months.</title>
        <time_frame>3 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>I-PORT</title>
            <description>I-PORT: The study will compare injecting Symlin and insulin into a multiple injection port (I-PORT) vs. standard injections.</description>
          </group>
          <group group_id="O2">
            <title>Standard Injections</title>
            <description>standard injections: The study will compare injecting Symlin and insulin into a multiple injection port (I-PORT) vs. standard injections.</description>
          </group>
        </group_list>
        <measure>
          <title>The Primary Outcome Will be Measured by HbA1c Values Taken at Screening, Baseline and After Three Months.</title>
          <units>% of HbA1c</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="17"/>
                <count group_id="O2" value="14"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Screening</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.68" spread=".65"/>
                    <measurement group_id="O2" value="7.93" spread=".73"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 3</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.34" spread=".60"/>
                    <measurement group_id="O2" value="7.42" spread=".90"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.66" spread=".35"/>
                    <measurement group_id="O2" value="7.70" spread=".67"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>The Secondary Outcome Will Measure Patient Satisfaction, Opinions and Attitudes Toward Using the Multiple Injection Port for Insulin and Symlin Administration Compared to Standard Symlin Injections (Measured Through Using Questionnaires).</title>
        <description>Scores from the QOL and treatment satisfaction measures collected at Visit 1 and Visit 6.&#xD;
To determine if patient satisfaction and patient opinions and attitudes toward using the I-PORT™ for insulin and Symlin® administration compared to standard insulin and Symlin® injections was significantly different for patients in the treatment and control groups, repeated-measures analysis of variance (RM-ANOVA) was conducted on scores from the quality of life and treatment satisfaction measures collected at Visit 1 and Visit 6. The RM-ANOVA results were evaluated to determine if any statistically significant changes occurred. TSQ- lower numbers show less satisfied. DDS- Lower numbers show decrease in distress. DTSQ- Lower numbers show less satisfied. One patient did not complete Visit 6 questionnaires.&#xD;
Scale ranges:&#xD;
DDS scale range: 17- 102 DTSQc scale range: 16- 96 Insulin /Symlin Treatment Satisfaction Questionnaire scale range: 15-90</description>
        <time_frame>3 months</time_frame>
        <population>Results broken down further to reflect results in each group: Iport vs. Standard Injection subjects and total number of subjects who completed the patient reports at visit 1 and Visit 6.</population>
        <group_list>
          <group group_id="O1">
            <title>Visit 1</title>
            <description>Patient reports at visit 1</description>
          </group>
          <group group_id="O2">
            <title>Visit 6</title>
            <description>Patient reports at last visit (3 months)</description>
          </group>
        </group_list>
        <measure>
          <title>The Secondary Outcome Will Measure Patient Satisfaction, Opinions and Attitudes Toward Using the Multiple Injection Port for Insulin and Symlin Administration Compared to Standard Symlin Injections (Measured Through Using Questionnaires).</title>
          <description>Scores from the QOL and treatment satisfaction measures collected at Visit 1 and Visit 6.&#xD;
To determine if patient satisfaction and patient opinions and attitudes toward using the I-PORT™ for insulin and Symlin® administration compared to standard insulin and Symlin® injections was significantly different for patients in the treatment and control groups, repeated-measures analysis of variance (RM-ANOVA) was conducted on scores from the quality of life and treatment satisfaction measures collected at Visit 1 and Visit 6. The RM-ANOVA results were evaluated to determine if any statistically significant changes occurred. TSQ- lower numbers show less satisfied. DDS- Lower numbers show decrease in distress. DTSQ- Lower numbers show less satisfied. One patient did not complete Visit 6 questionnaires.&#xD;
Scale ranges:&#xD;
DDS scale range: 17- 102 DTSQc scale range: 16- 96 Insulin /Symlin Treatment Satisfaction Questionnaire scale range: 15-90</description>
          <population>Results broken down further to reflect results in each group: Iport vs. Standard Injection subjects and total number of subjects who completed the patient reports at visit 1 and Visit 6.</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="31"/>
                <count group_id="O2" value="30"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Treatment Satisfaction Control</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="14"/>
                    <count group_id="O2" value="14"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="66.07" spread="13.34"/>
                    <measurement group_id="O2" value="65.66" spread="13.94"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Treatment Satisfaction Treatment</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="17"/>
                    <count group_id="O2" value="16"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="67.16" spread="12.30"/>
                    <measurement group_id="O2" value="54.28" spread="16.71"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>DTSQ Control</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="14"/>
                    <count group_id="O2" value="14"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="37.46" spread="5.95"/>
                    <measurement group_id="O2" value="34.54" spread="7.40"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>DTSQ Treatment</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="17"/>
                    <count group_id="O2" value="16"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="35.41" spread="6.78"/>
                    <measurement group_id="O2" value="33.25" spread="6.15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Diabetes Distress Scale Control</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="14"/>
                    <count group_id="O2" value="14"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="38.20" spread="10.56"/>
                    <measurement group_id="O2" value="33.86" spread="8.19"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Diabetes Distress Scale Treatment</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="17"/>
                    <count group_id="O2" value="16"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="34.00" spread="10.57"/>
                    <measurement group_id="O2" value="31.45" spread="10.74"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>The results were evaluated to determine if any statistically significant changes in any of these measures between the first and final visit occurred and if these changes were associated with membership in the treatment or control group.</groups_desc>
            <non_inferiority_type>Superiority or Other (legacy)</non_inferiority_type>
            <p_value>&gt;.05</p_value>
            <method>RM-ANOVA</method>
          </analysis>
        </analysis_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>2 years</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Iport</title>
          <description>Treatment group/ Iport Users</description>
        </group>
        <group group_id="E2">
          <title>Standard Injections</title>
          <description>Control group/ Standard Injections</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="14"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>1.7</frequency_threshold>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="11" subjects_at_risk="16"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="14"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Endocrine disorders</title>
            <event_list>
              <event>
                <sub_title>Hyperglycmia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="14"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Iritis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="14"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Abdominal pain</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="14"/>
              </event>
              <event>
                <sub_title>Bloating</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="14"/>
              </event>
              <event>
                <sub_title>Gastroenteritis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="14"/>
              </event>
              <event>
                <sub_title>Diarrhea</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="14"/>
              </event>
              <event>
                <sub_title>Black liquid stool</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="14"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="14"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Mettalic taste</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="14"/>
              </event>
              <event>
                <sub_title>mettalic smell</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="14"/>
              </event>
              <event>
                <sub_title>confusion</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="14"/>
              </event>
              <event>
                <sub_title>Boil</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="14"/>
              </event>
              <event>
                <sub_title>swollen lymph node</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="14"/>
              </event>
              <event>
                <sub_title>dizziness</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="14"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Upper respiratory infections</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="16"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="14"/>
              </event>
              <event>
                <sub_title>Urinary tract infections</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="16"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="14"/>
              </event>
              <event>
                <sub_title>Common Cold</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="14"/>
              </event>
              <event>
                <sub_title>Sinus infection</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="14"/>
              </event>
              <event>
                <sub_title>Yeast infection</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="14"/>
              </event>
              <event>
                <sub_title>Parvo Virus</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="14"/>
              </event>
              <event>
                <sub_title>tooth abcess</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="14"/>
              </event>
              <event>
                <sub_title>bacterial bronchitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="14"/>
              </event>
              <event>
                <sub_title>pneumonia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="14"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>left wrist fracture</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="14"/>
              </event>
              <event>
                <sub_title>Low back pain</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="14"/>
              </event>
              <event>
                <sub_title>Dental implants</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="14"/>
              </event>
              <event>
                <sub_title>Trigger finger release</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="14"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>uterine ablation</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="14"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Thomas Blevins,MD</name_or_title>
      <organization>Texas Diabetes &amp; Endocrinology</organization>
      <phone>5812.334.3505</phone>
      <email>blevins@texasdiabetes.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

